Alzheimer Drugs Market Size, Share, Industry, Forecast and outlook (2023-2030)

Alzheimer Drugs Market is segmented By Drugs Type (Donepezil, Galantamine, Rivastigmine, Memantine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2023-2030.

Alzheimer Drugs Market Overview

The Global Alzheimer Drugs Market reached USD 3.97 billion in 2022 and is projected to witness lucrative growth by reaching USD 7.7 billion by 2030. The Global Alzheimer Drugs Market is expected to exhibit a CAGR of 8.7% during the forecast period 2023-2030.  The rising incidence of chronic diseases like dementia, the expansion of the therapeutic pipeline, investments in biomarkers for drug development, and the development of more advanced diagnostics for early detection all contribute to the growth of the Global Alzheimer Drugs Market.  

The Global Alzheimer Drugs Market scope includes drugs types of Alzheimer’s drugs such as rivastigmine, donepezil or galantamine, leading to a surge in Alzheimer’s drugs market share. Furthermore, the usage of biomarkers for drug discovery is significantly increasing and is being highly researched by researchers. 

Alzheimer Drugs Market Scope

For Know more Insights  - Download Sample

Alzheimer Drugs Market Dynamics

Use of Biomarkers in Drug Development and Large Pipeline are Driving the Growth of the Alzheimer Drugs Market.

The global Alzheimer drugs market is expanding owing to the increasing research studies of Alzheimer’s drugs, utilization of biomarkers in drug development, rising geriatric population, and new novel technologically advanced therapies. 

The market growth is being further accelerated by the extensive research investigations being undertaken about Alzheimer disease. For instance, the Alzheimer's Association provided USD 1,000,000 to ImmunoBrain Checkpoint in October 2020 to support the Phase I clinical trial for "IBC-Ab002" as a treatment for Alzheimer's. 

Growing Research and Development and Rising Prevalence of Alzheimer Creates Lucrative Opportunities  for Manufacturers 

There is a growing market opportunity owing to growing expenditure on research and development proficiencies by key players for novel technological advancements. The rising prevalence of Alzheimer’s is also a market trend driving the market. 

The World Alzheimer Report estimates that approximately 50 million individuals worldwide currently have Alzheimer's disease or associated dementia, which is anticipated to increase to 152 million by the year 2050.

High failure Rates of Late-Stage Drugs will Hamper the Growth of the Market

However, the high cost of advanced medications, the failure of exploratory candidates in late stages, and the low awareness of alzheimer's disease in underdeveloped nations may restrain the global market for Alzheimer's medications over the projection period.

For instance, in November 2022, in two pharmacological trials, Roche's potential Alzheimer's treatment was unable to slow the progression of dementia, leaving competitors Biogen and Eisai in the lead in the high-stakes race to develop a cure for the illness that steals memory.

Alzheimer Drugs Market Segment Analysis

The Global Alzheimer Drugs Market is segmented based on drugs type, distribution channel and region.

Owing to the High Research, the Galantamine Drugs Type Segment Accounted for Approximately 38.7% of the Alzheimer Drugs Market Share in 2022.

Galantamine belongs to the group of drugs known as acetylcholinesterase inhibitors. It enhances the brain's supply of a particular naturally occurring compound required for memory and cognition. Galantamine helps people with Alzheimer's disease think and recall better or slow the loss of these skills. 

The three oral dosage forms of galantamine include tablets, extended-release (long-acting) capsules, and solutions (liquids). Galantamine may cause stomach discomfort, especially early in the course of treatment. Aricept, Exelon, and Razadyne are some medications approved by the US Food & Drug Administration as treatments for mild to moderate Alzheimer's.

Additionally, businesses are spending money on the creation of new medicines. In addition, a number of Alzheimer's medications, including Aducanumab, Solanezumab, and Insulin, are presently undergoing late-stage clinical trials. In the coming years, the development of these medications is predicted to drive market expansion.

Source: DataM Intelligence Analysis (2023)

Alzheimer Drugs Market Geographical Penetration

North America Accounted for Approximately 39.1% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment.

Due to the rising need for Alzheimer’s drugs for treatment purposes in healthcare, manufacturers in North America have a chance of increasing their operations. There are many producers and suppliers in North America and owing to the region’s rapid economic growth, industrial production has expanded, driving the demand for Alzheimer’s drugs. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for treatment, and increase in pharmaceutical establishment across the region are also contributing to the market growth in this region. Rising novel technology launches to support Alzheimer’s drugs usage for neurodegenerative disorders such as dementia also drives the market growth.   

Individuals are becoming more aware of various technologies or therapies being studies for the treatment leading to the expansion of the market in this region. The factors mentioned above further proves North America's dominance on a global scale.

Source: DataM Intelligence Analysis (2023)

Alzheimer Drugs Market Competitive Landscape

The major global players in the Alzheimer drugs market include F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, Lupin, Siemens Healthineers and AbbVie among others. 

COVID-19 Impact on Alzheimer Drugs Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the Global Alzheimer Drugs Market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the Global Alzheimer Drugs Market growth over the forecast period.

By Drugs Type

• Donepezil
• Galantamine
• Rivastigmine
• Memantine 
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On May 3, 2023, Positive findings from the TRAILBLAZER-ALZ 2 Phase III research, which demonstrated that donanemab significantly reduced cognitive and functional deterioration in persons with early-stage Alzheimer's disease, were released by Eli Lilly and Company. 

The integrated Alzheimer's Disease Rating Scale (iADRS) change from baseline to 18 months was achieved by donanemab. The iADRS's primary endpoint assesses cognition as well as daily activities like driving, operating a vehicle, engaging in hobbies, and having conversations about current events.

• On January 6, 2023, The U.S. Food and Drug Administration (FDA) approved lecanemab-irmb (LEQEMBI), an  immunoglobulin gamma 1 (IgG1) humanized monoclonal antibody aimed against aggregated insoluble and soluble forms of amyloid beta (A), for Alzheimer's disease (AD) treatment, according to a joint announcement by Eisai and Biogen. The approval was granted on Phase II data showing LEQEMBI decreased the buildup of A plaque in the brain, a characteristic of AD. 
• On June 7, 2021, The U.S. Food and Drug Administration (FDA) provided fast approval for ADUHELM (aducanumab-avwa), the first and only Alzheimer's disease medication to address a specific pathology of the illness by lowering amyloid beta plaques in the brain, according to a statement from Biogen and Eisai.

Why Purchase the Report?

• To visualize the Global Alzheimer Drugs Market segmentation based on drugs type, distribution channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of Alzheimer drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Alzheimer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Lifesciences and Healthcare related reports, please click here